Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $187.71 Average PT from Analysts

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has earned an average recommendation of “Moderate Buy” from the fourteen ratings firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $187.71.

A number of research analysts recently weighed in on JAZZ shares. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $179.00 in a research report on Friday, March 7th. JPMorgan Chase & Co. raised their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an “overweight” rating in a research report on Wednesday, February 26th. Piper Sandler reaffirmed an “overweight” rating and set a $176.00 price objective (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $130.00 to $170.00 in a research report on Thursday, February 13th. Finally, Barclays reissued an “overweight” rating and issued a $200.00 target price (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th.

Jazz Pharmaceuticals Stock Down 1.3 %

JAZZ stock opened at $138.76 on Wednesday. Jazz Pharmaceuticals has a twelve month low of $99.06 and a twelve month high of $148.06. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. The firm has a market cap of $8.43 billion, a PE ratio of 19.54, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The business has a 50 day moving average of $131.41 and a 200 day moving average of $121.79.

Insider Buying and Selling

In related news, CAO Patricia Carr sold 1,140 shares of Jazz Pharmaceuticals stock in a transaction on Monday, March 10th. The stock was sold at an average price of $137.81, for a total value of $157,103.40. Following the completion of the sale, the chief accounting officer now owns 7,012 shares of the company’s stock, valued at $966,323.72. The trade was a 13.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the completion of the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 28,736 shares of company stock valued at $4,022,825 over the last 90 days. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. IFP Advisors Inc purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC lifted its position in Jazz Pharmaceuticals by 97.1% during the fourth quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares in the last quarter. Elequin Capital LP lifted its position in Jazz Pharmaceuticals by 677.8% during the fourth quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares in the last quarter. CoreFirst Bank & Trust purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals during the fourth quarter valued at $29,000. 89.14% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.